- Home
- CLBT vs ICUI Comparison
CLBT vs ICUI Comparison
Compare CLBT & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLBT
- ICUI
- Stock Information
- Founded
- CLBT 1999
- ICUI 1984
- Country
- CLBT Israel
- ICUI United States
- Employees
- CLBT N/A
- ICUI N/A
- Industry
- CLBT Computer Software: Prepackaged Software
- ICUI Medical/Dental Instruments
- Sector
- CLBT Technology
- ICUI Health Care
- Exchange
- CLBT Nasdaq
- ICUI Nasdaq
- Market Cap
- CLBT 4.4B
- ICUI 3.8B
- IPO Year
- CLBT N/A
- ICUI 1992
- Fundamental
- Price
- CLBT $19.12
- ICUI $157.26
- Analyst Decision
- CLBT Strong Buy
- ICUI Buy
- Analyst Count
- CLBT 9
- ICUI 4
- Target Price
- CLBT $22.00
- ICUI $199.67
- AVG Volume (30 Days)
- CLBT 2.4M
- ICUI 184.7K
- Earning Date
- CLBT 02-13-2025
- ICUI 02-27-2025
- Dividend Yield
- CLBT N/A
- ICUI N/A
- EPS Growth
- CLBT N/A
- ICUI N/A
- EPS
- CLBT N/A
- ICUI N/A
- Revenue
- CLBT $401,203,000.00
- ICUI $2,340,097,000.00
- Revenue This Year
- CLBT $23.09
- ICUI $4.38
- Revenue Next Year
- CLBT $17.61
- ICUI $0.34
- P/E Ratio
- CLBT N/A
- ICUI N/A
- Revenue Growth
- CLBT 23.41
- ICUI 4.04
- 52 Week Low
- CLBT $10.25
- ICUI $93.36
- 52 Week High
- CLBT $26.30
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- CLBT 29.83
- ICUI 42.90
- Support Level
- CLBT $18.48
- ICUI $155.25
- Resistance Level
- CLBT $25.03
- ICUI $165.17
- Average True Range (ATR)
- CLBT 1.18
- ICUI 4.73
- MACD
- CLBT -0.77
- ICUI -0.09
- Stochastic Oscillator
- CLBT 8.18
- ICUI 19.81
About CLBT Cellebrite DI Ltd.
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.